Patents by Inventor David J. T. Porter

David J. T. Porter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Uracil reductase inactivators
    Patent number: 7704971
    Abstract: Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-flourouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, ido, cyano, halo-substituted C1-4 alkyl, C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 alkynyl.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: April 27, 2010
    Assignee: SmithKlineBeecham Corporation
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Uracil reductase inactivators
    Patent number: 7119096
    Abstract: Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-flourouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, ido, cyano, halo-substituted C1-4 alkyl, C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 alkynyl.
    Type: Grant
    Filed: October 1, 2001
    Date of Patent: October 10, 2006
    Assignee: SmithKlineBeecham Corporation
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Pharmaceutical compositions of 5-alkynyl uracil compounds
    Patent number: 6586440
    Abstract: This invention relates to pharmaceutical compositions of 5-alkynyluracil compounds in the form of tablets or capsules.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: July 1, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim
  • Uracil reductase inactivatores
    Patent number: 6297223
    Abstract: Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-fluorouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, iodo, cyano, halo-substituted C1-4 alkyl, C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 aklynyl.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: October 2, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Uracil reductase inactivators
    Patent number: 6268374
    Abstract: The present invention relates to a group of 5-substituted uracil derivatives which are inactivators of uracil reductase and which are particularly useful in cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: July 31, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Pharmaceutical compositions of 5-alkynyl-dideoxyribouracil
    Patent number: 6221852
    Abstract: This application relates to pharmaceutical compositions of 5-alkynyl-dideoxyridbouracils which generates 5-alkynyluracils in vivo, which are inactivators of uracil reductase.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: April 24, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim
  • Pharmaceutical compositions of 5-alkynyl uracil compounds
    Patent number: 6177436
    Abstract: This invention relates to pharmaceutical compositions of 5-alkynuracil.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: January 23, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim
  • Uracil reductase inactivators
    Patent number: 5817664
    Abstract: The present invention relates to a group of 5-substituted uracil derivatives which are inactivators of uracil reductase and which are particularily useful in cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil (5-FU).
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 6, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Pharmaceutical compositions of 5-substituted uracil compounds
    Patent number: 5643913
    Abstract: Pharmaceutical compositions containing 5-substituted uracil compounds are disclosed. The compositions are preferably in the form of a tablet or capsule.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: July 1, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim
  • 5'-O-propionyl and 5'-O-butyryl esters of 2-amino-6-methoxy-9-(.beta.-D-arabinofuranosyl)-9H-purine
    Patent number: 5539098
    Abstract: The 5'-O-proprionyl and 5'-O-butyryl esters of 2-amino-6-methoxy-9-(B-D-arabinofuranosyl)-9H-purine useful as inhibitors of varicella zoster virus.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: July 23, 1996
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas A. Krenitsky, David J. T. Porter
  • 9-.beta.-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine
    Patent number: 5424295
    Abstract: The compound 9-B-D-arabinofuranosyl-2-amino-6-methoxy-9H-purine along with its 5'-acetyl and 5'-(4-methoxy-4-oxobutyryl derivatives are disclosed as inhibitors of Varicella Zoster virus (VZV).
    Type: Grant
    Filed: August 23, 1993
    Date of Patent: June 13, 1995
    Assignee: Burroughs Wellcome Co.
    Inventors: Thomas A. Krenitsky, David J. T. Porter